In 2004, graphene was physically produced for the first time at Manchester University by using Sellotape to shear off thin layers of carbon. Its discoverers, Andre Geim and Kostya Novoselov went on to win a Noble Prize in physics for their findings in 2010. Since then, claims that electronics, vehicles and medicine will be transformed by the carbon-based material said to be both harder and lighter than steel, highly conductive and incredibly light have been rampant.
Paragraf Is Finding A Way To Bring Graphene To Diagnostics
The UK-based company is creating a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.

More from Financing
Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
Dublin-based Neuromod has closed a €10m ($10.9m) series B funding round to bring a "new standard of care" to patients with tinnitus.
More from Business
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.